An 18 Month Phase 2a Open Label, Randomized Study of Avastin, Lucentis, or Eylea (Anti-VEGF Therapy) Administered in Combination With Fovista (Anti-PDGF BB Pegylated Aptamer)

Trial Profile

An 18 Month Phase 2a Open Label, Randomized Study of Avastin, Lucentis, or Eylea (Anti-VEGF Therapy) Administered in Combination With Fovista (Anti-PDGF BB Pegylated Aptamer)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Pegpleranib (Primary) ; Aflibercept; Bevacizumab; Ranibizumab
  • Indications Age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Dec 2016 Status changed from active, no longer recruiting to discontinued.
    • 13 Apr 2016 Status changed from recruiting to active, no longer recruiting according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top